SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
CVS Health Corporation (CVS) trades at a trailing P/E of 57.0, forward P/E of 10.8. Trailing earnings yield is 1.75%, forward earnings yield 9.23%. PEG 0.03 (Peter Lynch undervalued ≤1.0). Graham Number is $43.12.
Criteria proven by this page:
- VALUE (45/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 10.8 (down from trailing 57.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.75% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 9.23% as earnings recover.
- Analyst consensus target $94.50 (+21.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 55/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
45/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — CVS
Valuation Multiples
P/E (TTM)57.0
Forward P/E10.8
PEG Ratio0.03
Forward PEG0.03
P/B Ratio1.34
P/S Ratio0.25
EV/EBITDA18.9
Per Share Data
EPS (TTM)$1.39
Forward EPS (Est.)$7.16
Book Value / Share$59.36
Revenue / Share$316.59
FCF / Share$6.15
Yields & Fair Value
Earnings Yield1.75%
Forward Earnings Yield9.23%
Dividend Yield3.35%
Graham Number$43.12
SharesGrow IV$445.93 (+474.5%)
Analyst Target$94.50 (+21.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
15.9 |
2.75 |
2.30 |
0.48 |
2.17% |
| 2017 |
11.2 |
0.36 |
1.96 |
0.40 |
2.77% |
| 2018 |
-115.2 |
1.06 |
1.17 |
0.35 |
2.98% |
| 2019 |
14.6 |
-0.01 |
1.51 |
0.38 |
2.69% |
| 2020 |
12.5 |
1.67 |
1.29 |
0.33 |
2.93% |
| 2021 |
17.0 |
1.79 |
1.81 |
0.47 |
1.93% |
| 2022 |
28.4 |
-0.63 |
1.71 |
0.38 |
2.38% |
| 2023 |
12.2 |
0.13 |
1.33 |
0.28 |
3.09% |
| 2024 |
12.2 |
-0.28 |
0.75 |
0.15 |
5.97% |
| 2025 |
56.9 |
-0.92 |
1.34 |
0.25 |
3.38% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$4.90 |
$177.55B |
$5.32B |
3% |
| 2017 |
$6.44 |
$184.79B |
$6.62B |
3.6% |
| 2018 |
$-0.57 |
$194.58B |
$-594M |
-0.3% |
| 2019 |
$5.08 |
$256.78B |
$6.63B |
2.6% |
| 2020 |
$5.46 |
$268.71B |
$7.18B |
2.7% |
| 2021 |
$5.95 |
$292.11B |
$8B |
2.7% |
| 2022 |
$3.26 |
$322.47B |
$4.31B |
1.3% |
| 2023 |
$6.47 |
$357.78B |
$8.34B |
2.3% |
| 2024 |
$3.66 |
$372.81B |
$4.61B |
1.2% |
| 2025 |
$1.39 |
$402.07B |
$1.77B |
0.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$7.17 |
$7.07 – $7.35 |
$404.92B |
$394.45B – $417.31B |
18 |
| 2027 |
$8.16 |
$7.96 – $8.35 |
$424.63B |
$408.06B – $442.04B |
17 |
| 2028 |
$9.41 |
$8.53 – $11.11 |
$447.92B |
$445.68B – $450.17B |
10 |
| 2029 |
$10.47 |
$10.04 – $11.09 |
$475.37B |
$460.55B – $497.04B |
4 |
| 2030 |
$11.47 |
$11.00 – $12.15 |
$495.6B |
$480.15B – $518.19B |
4 |
